Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AVENUE THERAPEUTICS, INC.

(ATXI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
1.53(c) 1.58(c) 1.56(c) 1.62(c) 1.58 Last
45 004 16 496 32 266 49 408 4 839 Volume
-1.29% +3.27% -1.27% +3.85% -2.47% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -3,74 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,04x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -3,59 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,36x
Yield 2022 -
Capitalization 27,1 M 27,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 4
Free-Float 39,6%
More Financials
Company
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The CompanyÔÇÖs product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid... 
More about the company
All news about AVENUE THERAPEUTICS, INC.
09/21AVENUE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
09/21Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Dru..
CI
09/03AVENUE THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
09/01AVENUE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
08/27Avenue Therapeutics, Inc. Receives an Appeal Denied Letter from the Office of Neuroscie..
CI
08/27AVENUE THERAPEUTICS : Appeal Seeking Approval for Pain Drug Denied by FDA
MT
08/27AVENUE THERAPEUTICS : FDA Denies Appeal of IV Tramadol NDA Rejection
DJ
08/27AVENUE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
08/27Avenue Therapeutics, Inc. Receives an Appeal Denied Letter from the Office of Neuroscie..
CI
08/16AVENUE THERAPEUTICS : Management's Discussion and Analysis of the Results of Operations
AQ
08/16Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
CI
07/29Avenue Therapeutics, Inc. Submits Formal Dispute Resolution Request to Food and Drug Ad..
CI
07/29AVENUE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
07/15AVENUE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
06/25AVENUE THERAPEUTICS, INC.(NASDAQCM : ATXI) dropped from Russell 2000 Growth-Defensive Inde..
CI
More news
News in other languages on AVENUE THERAPEUTICS, INC.
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on AVENUE THERAPEUTICS, INC.
More recommendations
Chart AVENUE THERAPEUTICS, INC.
Duration : Period :
Avenue Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVENUE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,62 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Lucy Lu President, Chief Executive Officer & Director
Joseph Vazzano Chief Financial Officer & Secretary
Lindsay Allan Rosenwald Executive Chairman
Scott A. Reines Chief Medical Officer
Neil Herskowitz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AVENUE THERAPEUTICS, INC.-72.77%27
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582